Abstract: A method of differentiating pluripotent stem cells into hemangioblasts comprising incubating the pluripotent stem cells in a first serum-free differentiation medium comprising bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF) and stem cell factor (SCF) to induce differentiation of the pluripotent stem cells into hemangioblasts or hemangioblast-containing embryoid bodies is provided. The hemangioblasts or embryoid bodies may be cultured in a second differentiation medium comprising at el least granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF) and interleukin-3 (IL-3) for a period of time sufficient to generate alveolar-like macrophages.

Abstract: Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturing the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.

Abstract: Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturing the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.

Abstract: A method of treating a respiratory viral infection in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of alveolar-like macrophages, or an anti-viral factor produced by alveolar-like macrophages.

Abstract: Alveolar-like macrophages and a method for generating alveolar-like macrophages from hemangioblasts is provided. The method comprises the steps of: i) culturing the hemangioblasts in a hematopoietic-inducing medium comprising vascular endothelial growth factor (VEGF), stem cell factor (SCF) and interleukin-3 (IL-3) for a sufficient period of time to generate macrophages, and ii) culturing the macrophages in an alveolar macrophage-inducing medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), and optionally macrophage colony stimulating factor (M-CSF), under suitable conditions and for a sufficient period of time to yield alveolar-like macrophages.

Abstract: The invention relates to reagents and methods for detecting, diagnosing and screening for conditions associated with hydroxylated hypoxia inducible factor 1-? (HIF-1?). The invention also relates to novel monoclonal antibodies specific for hydroxylated HIF-1?, or binding fragments thereof, and related nucleic acids, vectors, cells and compositions, as well as methods of using the antibodies in methods of the invention.

Abstract: The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are disclosed for evaluating conditions such as preeclampsia utilizing matador polypeptides and polynucleotides encoding same.

Abstract: The invention relates to reagents and methods for detecting, diagnosing and screening for conditions associated with hydroxylated hypoxia inducible factor 1-? (HIF-1?). The invention also relates to novel monoclonal antibodies specific for hydroxylated HIF-1?, or binding fragments thereof, and related nucleic acids, vectors, cells and compositions, as well as methods of using the antibodies in methods of the invention.

Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-?3, receptors of cytokines of the TGf? family, or HIF-1?.

Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-?3, receptors of cytokines of the TG? family, or HIF-1?.

Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-?3, receptors of cytokines of the TG? family, or HIF-1?.

Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-?3, receptors of cytokines of the TG? family, or HIF-1?.

Abstract: The invention provides a method for diagnosing in a subject a condition requiring modulation of or involving trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, comprising detecting HIF I? and the factors which modulate or are modulated by this protein, specifically TGF?3, sFLT, VEGF, SMAD2, 3 and 7, MtdP, MtdL, MclI 1, MclIc, VHL, SiahI, Siah2, ENG, and PHD. The invention also provides a method for diagnosing or distinguishing in a subject a specific condition requiring modulation of or involving trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, in particular early onset severe preeclampsia (EPE), late onset preeclampsia (LPE) and mtre-uterme growth restriction (IUGR) comprising detecting HLF I? and the factors which modulate or are modulated by this protein as defined above.

Abstract: The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are disclosed for evaluating conditions such as preeclampsia utilizing matador polypeptides and polynucleotides encoding same.

Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-?3, receptors of cytokines of the TG? family, or HIF-1?.

Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-beta 3, receptors of cytokines of the TG beta family, or HIF-1 alpha.

Abstract: Disclosed are methods and compositions that are useful in the detection and therapy of diseases (e.g., emphysema) and damage that afflict the lungs. In some aspects, the compositions comprise a formulation enriched for a species of phosphatidylcholine, such as palmitoylmyristoyl phosphatidylcholine (16:0/14:0PC). The compositions may further be described as lung surfactant supplement preparations particularly useful in the treatment of pulmonary diseases and afflictions prevalent among premature infants, and in particular, Respiratory Distress Syndrome (RDS). A PC marker is also disclosed, 16:0/14:0PC, that may be used to detect pulmonary disease or reduced/compromised alveolar function in an animal. Phospholipid profiles of 16:0/14:0PC, 16:0/16:1PC and 16:0/16:0PC are also provided, and are correlated with particular pulmonary diseased states.

Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-beta 3, receptors of cytokines of the TG beta family, or HIF-1 alpha.

Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-?3, receptors of cytokines of the TG? family, or HIF-1?.

Abstract: A method for determining the thermal material properties of metal shaped parts from a model is disclosed, which describes the thermal material properties of the metal shaped part. At least one thermodynamic parameter (p) is formed as a linear combination consisting of at least one base function (hi) and of at least one weighting factor (gi), whereby the base function (hi) describes the thermal material properties, and the weighting factor (gi) takes the influence of the alloying elements on at least one thermodynamic parameter (p) into account. The method makes it possible to conduct a sufficiently precise determination of the thermal material properties with a smaller time requirement.